Join Growin Stock Community!

Metagenomi, inc. common stockMGX.US Overview

US StockHealthcare
(No presentation for MGX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MGX AI Insights

MGX Overall Performance

MGX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MGX Recent Performance

0.99%

Metagenomi, inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

MGX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MGX Key Information

MGX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MGX Profile

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Price of MGX

MGX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MGX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.85
PB Ratio
0.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-287.06%
Revenue Growth (YoY)
-43.88%
Profit Growth (YoY)
-43.88%
3-Year Revenue Growth
20.79%
3-Year Profit Growth
25.12%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.85
PB Ratio
0.34
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-287.06%
Revenue Growth (YoY)
-43.88%
Profit Growth (YoY)
-43.88%
3-Year Revenue Growth
20.79%
3-Year Profit Growth
25.12%
  • When is MGX's latest earnings report released?

    The most recent financial report for Metagenomi, inc. common stock (MGX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MGX's short-term business performance and financial health. For the latest updates on MGX's earnings releases, visit this page regularly.

  • What is the operating profit of MGX?

    According to the latest financial report, Metagenomi, inc. common stock (MGX) reported an Operating Profit of -22.84M with an Operating Margin of -263.76% this period, representing a decline of 2.04% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MGX's revenue growth?

    In the latest financial report, Metagenomi, inc. common stock (MGX) announced revenue of 8.66M, with a Year-Over-Year growth rate of -24.8%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does MGX have?

    As of the end of the reporting period, Metagenomi, inc. common stock (MGX) had total debt of 41.66M, with a debt ratio of 0.17. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MGX have?

    At the end of the period, Metagenomi, inc. common stock (MGX) held Total Cash and Cash Equivalents of 38.02M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MGX go with three margins increasing?

    In the latest report, Metagenomi, inc. common stock (MGX) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -263.76%%, and net margin of -235.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MGX's profit trajectory and future growth potential.

  • Is MGX's EPS continuing to grow?

    According to the past four quarterly reports, Metagenomi, inc. common stock (MGX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.55. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MGX?

    Metagenomi, inc. common stock (MGX)'s Free Cash Flow (FCF) for the period is -21.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 23.39% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.